A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial

Health Technology Assessment

Volumn 11, Issue 37, 2007, Pages 1-108

  Marson, A G ^a   Appleton, R ^b   Baker, G A ^a   Chadwick, D W ^a   Doughty, J ^c   Eaton, B ^a   Gamble, C ^a   Jacoby, A ^a   Shackley, P ^d   Smith, D F ^e   Tudur Smith, C ^a   Vanoli, A ^d   Williamson, P R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; FRUCTOSE; TRIAZINE DERIVATIVE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; AGE; AGED; AGGRESSION; AGITATION; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTHRITIS; ARTICLE; ASTHMA; ATAXIA; BEHAVIOR DISORDER; BLADDER STONE; BLEEDING; BLOOD TOXICITY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHEST INFECTION; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DISEASE CONTROL; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; DYSPNEA; ECZEMA; ENDOCRINE DISEASE; EPILEPSY; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOCAL EPILEPSY; GASTROINTESTINAL TOXICITY; GENERALIZED EPILEPSY; GENITAL SYSTEM DISEASE; GINGIVA DISEASE; HALLUCINATION; HEALTH CARE COST; HEALTH ECONOMICS; HEARING DISORDER; HEART INFARCTION; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; IMPOTENCE; INFECTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LETHARGY; LIBIDO DISORDER; LIVER FUNCTION TEST; LONG TERM CARE; LUNG TOXICITY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MOUTH DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; PANCREATITIS; PATIENT COMPLIANCE; PEPTIC ULCER; PERSONALITY; PERSONALITY DISORDER; PSORIASIS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT DISEASE; RHINORRHEA; SEIZURE; SIDE EFFECT; SINUSITIS; SKIN APPENDAGE DISEASE; SKIN BRUISING; SKIN DISEASE; SKIN TOXICITY; SLEEP DISORDER; STANDARD; SYNCOPE; TACHYCARDIA; THOUGHT DISORDER; THYROID DISEASE; TINNITUS; TOXIC HEPATITIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE RETENTION; UROGENITAL TRACT DISEASE; VAGINA BLEEDING; VASCULAR DISEASE; VEIN THROMBOSIS; VERTIGO; VISUAL DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ECONOMICS; HEALTH STATUS INDICATOR; TREATMENT OUTCOME;

ADULT; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; FEMALE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HEALTH STATUS INDICATORS; HUMANS; MALE; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 35948991191     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11370     Document Type: Article

References (91)

1. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos Publications; 1990.
2. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-37.
3. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346:140-4.
4. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26:451-60.
5. Begley CE, Famulari M, Annegers JF, Lairson DR, Reynolds TF, Coan S, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41:342-51.
6. Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998;39:776-86.
7. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a UK community study. Epilepsia 1996;37:148-61.
8. NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20. London: National Institute for Health and Clinical Excellence; 2004.
9. Mattson R, Cramer J, Collins J. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-71.
10. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58:44-50.
11. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994;57:682-7.
12. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995;37:97-108.
13. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-13.
14. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002;43:505-13.
15. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000;(3):CD001030.
16. Tudur-Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001; (4):CD001769.
17. Tudur-Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002;(2):CD001911.
18. Taylor S, Tudur-Smith C, Williamson PR, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev 2001;(4):CD002217.
19. Tudur-Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev 2003;(1):CD001904.
20. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313:1169-74.
21. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27:195-204.
22. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/ Carbamazepine Monotherapy Trial Group [published erratum appears in Lancet 1995;345:662]. Lancet 1995;345:476-9.
23. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo A, et. al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998;51:1282-8.
24. Guerreiro MM, Vigonius U, Pohlmann H, de-Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27:205-13.
25. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3:70-6.
26. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996; 23:149-55.
27. Kalviainen R, Aikia M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52:989-96.
28. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
29. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
30. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354:13-19.
31. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
32. Brodie MJ, Bomhof MAM, Kalviainen R, Beran R, Richens A, Edwards D, et al. Double-blind comparison of tiagabine and carbamazepine monotherapy in newly diagnosed epilepsy. Epilepsia 1997;38 (Suppl 3):66-7.
33. Brodie MJ, Wroe SJ, Dean ADP, Holdich TAH, Whitehead J, Stevens JW. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 2002;3:140-6.
34. Anhut H, Greiner MJ, Murray GH, International GBP Monotherapy Study Group 945-77/78. Double-blind, fixed-dose comparison study of gabapentin (GBP; Neurontin®) and carbamazepine (CBZ) monotherapy in patients with newly diagnosed partial epilepsy. Epilepsia 1995;36 (Suppl 4):67.
35. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107:165-75.
36. NICE. Newer drugs for epilepsy in adults. Technology Appraisal Guidance 76. London: National Institute for Health and Clinical Excellence; 2004.
37. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
38. NICE. Newer drugs for epilepsy in children. Technology Appraisal Guidance 79. London: National Institute for Clinical Excellence; 2004.
39. MRC. Guidelines for good clinical practice in clinical trials. London: Medical Research Council; 1998.
40. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
41. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
42. Williamson P, Hutton J, Marson A, Chadwick D. Individual patient data meta-analyses for time to event outcomes: an example from epilepsy. Control Clin Trials 1997;18(3 Suppl 1):S184.
43. Spilker B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996.
44. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998;2(14).
45. Baker GA, Camfield C, Camfield P, Cramer JA, Elger CE, Johnson AL, et al. Commission on outcome measurement in epilepsy, 1994-1997: final report. Epilepsia 1998;39:213-31.
46. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9:375-9.
47. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003;60:1483-8.
48. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002;58 (8 Suppl 5):S9-20.
49. Bullinger M. Indices versus profiles - advantages and disadvantages. In Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990s. Lancaster: Kluwer; 1993.
50. Baker GA, Jacoby A, Smith D, Dewey M, Johnson A, Chadwick D. Quality of life in epilepsy: the Liverpool initiative. In Trimble MR, Dodson WE, editors. Epilepsy and quality of life. New York: Raven Press; 1994. pp. 135-50.
51. Abetz L, Jacoby A, Baker GA, McNulty P. Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL. Epilepsia 2000;41:1119-28.
52. Baker GA, Smith DF, Dewey M, Jacoby A, Chadwick DW. The initial development of a health-related quality of life model as an outcome measure in epilepsy. Epilepsy Res 1993;16:65-81.
53. Andrews FM, Withey SB. Social indicators of well-being: Americans' perceptions of life quality. New York: Plenum Press; 1976.
54. Theunissen NC, Vogels TO, Koopman HM, Verrips GH, Zwinderman KA, Verloove-Vanhorick SP, et al. The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res 1998;7:387-97.
55. Rutter M, Graham P, Yule W. A neuropsychiatric study in childhood. Clinics in Developmental Medicine Nos 35/36. London: Spastics International and Heinemann Medical; 1970.
56. Baker GA, Frances P, Middleton E, Jacoby A, Schapel GJ, Defalla B, et al. Initial development, reliability and validity of a patient-based adverse drug event scale. Epilepsia 1994;35 (Suppl 7):80.
57. Landgraf JM, Abetz L, Ware JE. The child health questionnaire users' manual. 1st ed. Boston, MA: The Health Institute, New England Medical Center; 1996.
58. Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res 1998; 7:399-407.
59. Cramer JA, Westbrook LE, Devinsky O, Perrine K, Glassman MB, Camfield C. Development of the quality of life in epilepsy inventory for adolescents: the QOLIE-AD-48. Epilepsia 1999;40:1114-21.
60. British Medical Association. British National Formulary 49. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2005.
61. Curtis L, Netten A. Unit costs of health and social care. Canterbury: PSSRU, University of Kent; 2005.
62. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
63. Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ 2004;13:1203-10.
64. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002;11:455-68.
65. Claxton K, Fenwick E, Sculpher M. Decision-making with uncertainty: the value of information. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar, 2006. pp. 514-25.
66. Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39:799-803.
67. Wiebe S, Eliaszur M, Matijevic S. Changes in QOL in epilepsy: how large must they be to real? Epilepsia 2001;42:113-18.
68. Mattson R, Cramer J, Collins J. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-71.
69. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
70. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database Syst Rev 2000; (3):CD001030.
71. Jones B, Jarvis P, Lewis JA, Ebutt AF. Trials to assess equivalence; the importance of rigorous methods. BMJ 1996;313:36-9.
72. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005;365:2007-13.
73. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:1175-80.
74. Donald MN. Implications of non-response for the interpretation of mail questionnaire data. Public Opinion Quarterly 1960; 24:99-114.
75. Goyden J. The silent minority: non-respondents to sample surveys. Cambridge: Polity Press; 1987.
76. Messenheimer JA, Guberman AH. Rash with lamotrigine: dosing guidelines. Epilepsia 2000;41:488.
77. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33:1037-42.
78. Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthrnan BM, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868-73.
79. Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006;66:1310-17.
80. Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
81. Adab N, Kini U, Vinten J, Ayres J, Baler G, Clayton-Smith J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75:1575-83.
82. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12.
83. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39:495-501.
84. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737-43.
85. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2005; (4):CD003032.
86. McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, et al. Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technol Assess 2001;5(31).
87. Little RJA, Rubin DB. Statistical analysis with missing data. Hoboken, NJ: Wiley; 2002.
88. Moser CA. Kalton G. Survey methods in social investigation. Aldershot: Gower; 1971.
89. Fiset L, Milgrom P, Tarnai J. Dentists' response to financial incentives in a mail survey of malpractice liability experience. J Public Health Dent 1994;54:68-72.
90. Fowler FJ. Survey research method. Beverley Hills, CA: Sage; 1993.
91. Mangione TW. Mail surveys: improving the quality. Thousand Oaks, CA: Sage; 1995.